, Tracking Stock Market Picks
Enter Symbol:

up 871.62 %

PHARMASSET INC. (VRUS) rated Overweight with price target $35 by JP Morgan

Posted on: Tuesday,  Apr 13, 2010  8:25 AM ET by JP Morgan

JP Morgan rated Overweight PHARMASSET INC. (NASDAQ: VRUS) on 04/13/2010, when the stock price was $14.10. Since
then, PHARMASSET INC. has gained 871.62% as of 01/17/2012's recent price of $136.95.
If you would have followed this JP Morgan's recommendation on VRUS, you would have gained 871.62% of your investment in 644 days.

Pharmasset, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of drugs to treat viral infections. It focuses on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV).

JPMorgan is a leading financial services firm with one of the largest client franchises in the world. We partner with our clients to offer the most complete and innovative solutions in the industry to help them achieve their goals. For more than 200 years, we have taken a long-term approach to our clients and to the way we conduct business. Our firm has grown considerably in scale and scope, but our commitment to our core principle of doing "only first-class business... in a first-class way" has never been stronger.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/13/2010 8:25 AM Buy
14.10 17.50
as of 8/27/2015
1 Week   
1 Month   
3 Months   
1 YTD up  871.76 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy